



SYSTEMATIC REVIEW

A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa [version 1; referees: 2 approved, 1 approved with reservations]

John W. Frew , Jason E. Hawkes , James G. Krueger

Laboratory for Investigative Dermatology, Rockefeller University, New York, NY, 10065, USA

v1 First published: 13 Dec 2018, 7:1930 (<https://doi.org/10.12688/f1000research.17267.1>)
 Latest published: 13 Dec 2018, 7:1930 (<https://doi.org/10.12688/f1000research.17267.1>)

Abstract

Background: The pathogenesis of hidradenitis suppurativa (HS) remains unclear. In order to develop effective treatment strategies, a deeper understanding of pathophysiology is needed. This is impaired by multiple small studies with inconsistent methodologies and the impact of co-occurring pro-inflammatory conditions such as smoking and obesity.

Methods: This systematic review aimed to collate all published reports of cytokine studies in tissue, blood, serum and exudate. It was registered with PROSPERO (Registration number CRD42018104664) performed in line with the PRISMA checklist.

Results: 19 studies were identified comprising 564 individual HS patients and 198 control patients examining 81 discrete cytokines. Methodology was highly varied and the quality of studies was generally low. There was a large degree of variance between the measured levels of cytokines. 78.2% of cytokines demonstrated heterogeneity by the chi-squared test for homogeneity and hence meta-analysis was not deemed appropriate. However, a strong and significant IL-17 signalling component was identified.




Conclusions: Cytokines consistently elevated in lesional, peri-lesional and unaffected tissue are identified and discussed. Areas for further investigation include the role of dendritic cells in HS; the contribution of obesity, smoking, diabetes and the microbiome to cytokine profiles in HS; and examining the natural history of this disease through longitudinal measurements of cytokines over time.




Keywords

Hidradenitis Suppurativa, Cytokines, Inflammation, Pathogenesis, IL-17, TNF-alpha

Open Peer Review

Referee Status:   

	Invited Referees		
	1	2	3
version 1 published 13 Dec 2018	 report	 report	 report

- Barbara Horváth** , University of Groningen, The Netherlands
Lisette Prens, University of Groningen, The Netherlands
- Aude Nassif** , Institut Pasteur, Medical Center, France
- Evangelos Giamarellos-Bourboulis** , Attikon University Hospital, Greece
National and Kapodistrian University of Athens, Greece

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: John W. Frew (jwfrew@gmail.com)

Author roles: **Frew JW:** Conceptualization, Data Curation, Formal Analysis, Methodology, Writing – Original Draft Preparation; **Hawkes JE:** Data Curation, Formal Analysis, Writing – Original Draft Preparation, Writing – Review & Editing; **Krueger JG:** Methodology, Supervision, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: Supported in part by a grant from the National Center for Advancing Translational Sciences (NCATS) [UL1 TR001866], National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Frew JW *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Frew JW, Hawkes JE and Krueger JG. **A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa [version 1; referees: 2 approved, 1 approved with reservations]** *F1000Research* 2018, 7:1930 (<https://doi.org/10.12688/f1000research.17267.1>)

First published: 13 Dec 2018, 7:1930 (<https://doi.org/10.12688/f1000research.17267.1>)

Introduction

Hidradenitis Suppurativa (HS) is a chronic inflammatory disease, the exact pathophysiology of which remains poorly defined¹. Dysregulation of the T_h17: Treg axis², IL-36 signalling pathways³ and keratinocyte-mediated inflammatory cytokines⁴ have been demonstrated in lesional skin, blood, serum, and exudate^{5–8} although contradictory results exist^{4,9}. Given the variable and incomplete response of patients to treatment, including monoclonal antibodies¹, some authors have proposed clinical^{10,11}, and immunological⁵ subtypes of HS in an effort to better predict treatment outcome and response. Thus far, no current schema accurately predicts treatment efficacy.

In order to develop and implement effective treatment strategies in HS, a deeper understanding of the underlying inflammatory pathophysiology is needed. However, due to the heterogeneity of sampling methods, laboratory processing methods and data analysis, comparison across studies is problematic and potentially biased or inaccurate¹². Heterogeneity of tissue sampling and laboratory techniques alone may explain the inconsistent and conflicting results regarding specific cytokines,^{4,9} however, no systematic analysis of cytokine studies has been undertaken to compare results, methodology, and analytical techniques.

An additional complicating factor is that clinical comorbidities, which are strongly associated with disease activity in HS, such as obesity¹³, diabetes¹⁴, inflammatory bowel disease¹⁵, and smoking¹⁶, also produce pro-inflammatory cytokines, which affect multiple organ systems including the skin^{15,17–19}. Hence, it remains unclear whether the presence or absence of these conditions confound the findings of cytokine studies in HS, and whether clinical stratification of patients is necessary to identify significant pathogenic pathways, which may be amenable to pharmacological intervention. Critical evaluation and analysis of existing studies may also enable meta-analysis, which may identify cytokines, which, in smaller studies, do not have sufficient power to meet statistical significance when compared to controls.

Objectives

The objectives of this systematic review are:

- 1) To collate and describe all published reports of human cytokine studies in HS including those in skin, blood, serum and exudate.
- 2) To critically evaluate the sampling, laboratory and analysis techniques used in each study to assess whether comparisons can be made across individual studies.
- 3) To analyze the heterogeneity of published studies enable meta-analysis

Methods

This systematic review was registered with PROSPERO²⁰ (Registration number CRD42018104664) and was conducted in line with the PRISMA checklist²¹

Data sources

Information sources for this review included PubMed (1946-July 1 2018), Scopus (2004- July 1 2018) and Web of Science (1990-July 1 2018) as shown in Figure 1. Search strategy is presented in Table 1

Study eligibility criteria

Eligibility criteria for this review included cohort studies, case-control studies and other observational studies with no restrictions of patient age, sex, ethnicity or language of publication. Eligible studies included:

- 1) Studies reporting the results of cytokine investigations (in cutaneous tissue, serum, blood or exudate) in human subjects clinically diagnosed with hidradenitis suppurativa.

Studies deemed not eligible included those which:

- 1) Provide no new data but a review or summary of previously published data
- 2) Provide no comparison with controls or non-lesional tissue

Appraisal and synthesis methods

Data collection was performed independently by 2 authors (JWF & JEH), with any disagreements regarding inclusion of citations being referred to a third author (JGK) for mediation. Information was collected using a standardized data collection form (available as Extended data²²) with the principal outcomes of interest being the cytokine of interest, measured level of cytokine in lesional HS skin or serum. Comparison data against either peri-lesional, unaffected or control skin or serum was also collated. If data from individual patients was not available then the aggregate data including average change and statistical analyses of the significance of change was collected.

For each individual cytokine, where more than one study reported results, heterogeneity was assessed using the chi-squared tests for homogeneity. Homogeneity was defined as a chi squared value >0.05. All statistical analysis was undertaken using R (version 3.5.1)

Potential sources of bias in the identified studies are acknowledged including the small size of patient cohorts, the variability in sampling, laboratory techniques and the inclusion of patients being treated with a wide-variety of medications including immunosuppressants. Bias was also assessed using the NIH quality assessment tool for observational studies²³.

Results

A total of 367 non-duplicated citations were identified in the literature review (Figure 1). 343 of these articles were removed upon review of titles and abstracts against the pre-defined eligibility criteria. Full text review of the remaining 24 articles excluded




Figure 1. PRISMA Flowchart.

Table 1. Search Strategy.

Resources:	
1)	Pubmed (1946-July 1 2018),
2)	Scopus (2004- July 1 2018)
3)	Web of Science (1990-July 1 2018)
4)	Published Abstracts
5)	Contact with Authors for abstracts without full text for clarification of data and methodology
Pubmed Search Strategy:	
acne inversa OR apocrine acne OR apocrinitis OR Fox-den disease OR hidradenitis axillaris OR HS OR pyoderma sinifica fistulans OR Velpeau's disease OR Verneuil's disease OR Hidradenitidis Suppurative AND Cytokine OR chemokine OR inflammatory mediator	

5 review articles providing no new data. The remaining 19 studies^{2-9,24-33} included the results of 564 individual HS patients and 198 control patients, which were included in this systematic review.

Demographics

The summarized demographic data of the patients and controls comprising this review are included in Table 2. The 564 reported cases comprised of 231 males (40.9% reported cases) and 333 females (59.0%). 24 cases were unreported (4.1%). The average age was 38.5 years (n=560, 18 cases unreported). 141 individuals were current smokers (82.4%

reported cases), 8 ex-smokers (4.7% reported cases), 22 non-smokers (12.8% reported cases) and 407 unreported. Obesity (BMI>30) was reported in 85 individuals (42.5% reported cases), with 115 (57.5%) individuals non-obese (BMI<30) and unreported in 378 cases. 8 cases reported diabetes mellitus out of 24 reports (33% of reported cases). 12/38 cases reported a positive family history of HS (31.6% reported cases). Hurley Stage was reported as stage 1 in 68 individuals (17.4% reported), stage 2 in 199 individuals (51% reported cases) and stage 3 in 123 individuals (31.6% reported cases) with 188 cases going unreported. The average mHSS (modified hidradenitis suppurativa score) was 78.1 (n=247 cases). Biopsies were largely taken

Table 2. Demographic data of included studies.

Number of HS Patients	Male	Female	Mean Age (Years)	Comorbidities			Biopsy Sites			Hurley Staging	mHSS Score (Mean)	Therapy	Study Reference
				Smoking	Obesity (BMI>30)	Diabetes	Family History	Axillae	Groin				
17		1	45	Ex	Y	NR	NR	Serum Measurements			2	Thyroxine	2
		1	39	Y	N	NR	NR				2	N	
		1	24	N	N	NR	NR				2	N	
		1	41	Y	Y	NR	NR				2	N	
		1	23	Ex	Y	NR	NR				1	N	
		1	35	Y	Y	NR	NR				2	N	
		1	30	Y	N	NR	NR				2	Metformin	
		1	41	Y	Y	NR	NR				3	Clindamycin, Rifampicin	
		1	35	Y	Y	NR	NR				3	Metformin	
		1	47	Y	N	NR	NR				3	N	
	1		19	N	N	NR	NR				1	N	
	1		34	Y	N	NR	NR				2	Adalimumab	
		1	47	N	N	NR	NR				3	Adalimumab, Doxycycline	
		1	32	Y	N	NR	NR				2	Adalimumab	
	1	38	Y	N	NR	NR				3	Adalimumab, Doxycycline		
	1	24	Y	Y	NR	NR				2	Adalimumab		
	1	26	E	Y	NR	NR				2	Adalimumab		
18	11	7	(Range 19-62)	NR	NR	NR	NR	N=9	N=4	N=2	NR	NR	24
15	6	9	38.7	NR	NR	NR	NR	Stage 1=0 Stage 2=10 Stage 3=5			NR	N	3

Number of HS Patients	Male	Female	Mean Age (Years)	Comorbidities				Biopsy Sites			Hurley Staging	mHSS Score (Mean)	Therapy	Study Reference		
				Smoking	Obesity (BMI>30)	Diabetes	Family History	Axillae	Groin	Genital						
18	1	1	38	N	Y	NR	N	NR	NR	NR	NR	NR	3	54	N	4
	1		42	Y	N	NR	N	NR	NR	NR	NR	NR	3	56	N	
	1		30	N	Y	NR	Y	NR	NR	NR	NR	NR	3	57	Tetracycline	
		1		43	Y	N	NR	N	NR	NR	NR	NR	1	11	Tetracycline	
		1		32	N	Y	NR	Y	NR	NR	NR	NR	1	14	Tetracycline	
		1		14	N	N	NR	N	NR	NR	NR	NR	3	65	Rifampicin, Clindamycin	
		1		47	Y	N	NR	N	NR	NR	NR	NR	3	44	Tetracycline	
		1		43	Y	Y	NR	N	NR	NR	NR	NR	3	22	N	
		1		21	Y	N	NR	N	NR	NR	NR	NR	1	13	Tetracycline	
		1		47	N	N	NR	N	NR	NR	NR	NR	1	11	Tetracycline	
		1		27	Y	N	NR	N	NR	NR	NR	NR	2	7	Tetracycline	
		1		22	N	N	NR	Y	NR	NR	NR	NR	3	68	N	
	1			50	Y	N	NR	Y	NR	NR	NR	NR	2	46	N	
		1		23	N	N	NR	Y	NR	NR	NR	NR	2	22	N	
		1		19	Y	Y	NR	N	NR	NR	NR	NR	2	26	N	
		1		44	Y	N	NR	Y	NR	NR	NR	NR	2	14	N	
	1			22	Y	N	NR	N	NR	NR	NR	NR	3	23	N	
		1		20	N	N	NR	Y	NR	NR	NR	NR	2	21	Tetracycline	
	1		48	Y	N	NR	N	NR	NR	NR	NR	3	NR	Rifampicin, Clindamycin		
1			25	Y	N	NR	N	NR	NR	NR	NR	2	NR	Amoxicillin+ Clav Acid		
	1		20	N	N	NR	N	NR	NR	NR	NR	2	NR	N		
	1		31	N	Y	NR	N	NR	NR	NR	NR	3	NR	Adalimumab		
1			40	NA	NA	NR	NA	NR	NR	NR	NR	3	NR	N		
	1		46	Y	N	NR	N	NR	NR	NR	NR	3	NR	Tetracycline		
	1		26	Y	N	NR	N	NR	NR	NR	NR	2	NR	Azithromycin		
	1		36	Y	N	NR	N	NR	NR	NR	NR	2	NR	Amoxicillin+ Clav Acid		
	1		29	N	N	NR	Y	NR	NR	NR	NR	2	NR	Amoxicillin+ Clav Acid		

Number of HS Patients	Male	Female	Mean Age (Years)	Comorbidities				Biopsy Sites			Hurley Staging	mHSS Score (Mean)	Therapy	Study Reference
				Smoking	Obesity (BMI>30)	Diabetes	Family History	Axillae	Groin	Genital				
24	8	16	36.5 (Range 21–51)	NR	NR	NR	NR	NR	NR	NR	NR	Untreated	7	
74	36	38	37.4 (SD=12.0)	NR	N=32 (43.2%)	NR	NR	Serum Measurements	Serum Measurements	Stage 1= 11 Stage 2=47 Stage 3=16	NR	All on treatment (Not further elaborated)	8	
8	4	4	41.61 (SD=13.81)	N=5 Y=2 Ex=1	NR	N=4	NR	Exudate Measurements		Stage 1=0 Stage 2=3 Stage 3=5	68.88 (SD=41.45)	NR	6	
19	11	8	45.6 (SD=10.7)	N=14 (74%)	N=13 (68.4%)	NR	NR	Serum Measurements	Serum Measurements	Stage 1=0 Stage 2=9 Stage 3=10	82.79 (SD 41.0)	NR	25	
120	43	77	37.3 (SD=5.9)	NR	NR	NR	NR	Serum Measurements	Serum Measurements	Stage 1=39 Stage 2=52.4 Stage 3=44	28.1 (SD=20.2) 52.4 (SD=24.9) 129.3 (SD=79.2)	NR	5	
44	13	31	39.1 (SD=11.4)	Y=34 Ex=4	N=16	NR	NR	NR	NR	Stage 1=5 Stage 2=27 Stage 3=12	NR	N=15 Rifampicin, Clindamycin N=1 Minocycline N=2 Adalimumab n=2 Infliximab n=24 untreated	31	
22	10	12	38.2 (Range 19–60)	NR	NR	NR	NR	NR	NR	NR	NR	NR	30	
3	1	1	54	NR	NR	NR	NR	NR	NR	NR	NR	NR	9	
10	5	5	42 (Range 21–49)	NR	NR	NR	NR	NR	NR	NR	NR	NR	32	
20	8	12	37.5 (Range 21–51)	N=18	N=10	NR	NR	NR	NR	Stage 2 (100%)	NR	Treatment Withheld	29	
25	9	16	36 (Range 18–51)	NR	NR	NR	NR	NR	NR	NR	NR	Treatment Withheld (8 weeks prior)	28	
47	19	28	42.3 (Range 22–54)	NR	NR	NR	NR	Serum Measurements	Serum Measurements	Mean =2.16 (SD=0.55)	NR	Treatment Withheld (3 weeks prior)	27	
11	9	2	39.6 (Range 18–61)	NR	NR	NR	NR	NR	NR	"Mod-Severe Disease"	48.3 (Range 8–144)	NR	NR	

Number of HS Patients	Male	Female	Mean Age (Years)	Comorbidities			Biopsy Sites			Hurley Staging	mHSS Score (Mean)	Therapy	Study Reference	
				Smoking	Obesity (BMI>30)	Diabetes	Family History	Axillae	Groin					Genital
20	6	14	40 (SD=15)	19	27.6 (4.1)	NR	NR	7	12	1	Stage 1=4 Stage 2=11 Stage 3=5	Treatment withheld 3 weeks prior	26	
10	1	9	38 (SD=15)	10	28.9 (SD 4.5)	NR	NR	3	7	0	Stage1=2 Stage2=7 Stage3=1	Treatment Withheld 3 weeks prior		
10	7	3	46.6 (SD=15.1)	10	29.4 (4.7)	3	2	Serum			Stage 3=10	MABp1	33	
10	6	4	49.3 (SD=9.8)	8	27.9 (7.1)	1	2				Stage 2=2 Stage 3=8	No Treatment		
TOTAL: 564	231	333	38.5	141	85 (Of 200)	8 (of 24)	12	32	35	6	Stage 1 = 68 Stage 2 =199 Stage 3 =123	Average =78.1 (n=247)	Clindamycin+ Rifampicin=18; Adalimumab=26; Metformin=2; Treatment withheld= 85; Thyroxine=1; MABp1=10; Tetracyclines=12; No Treatment=86; Not Specified=74; Infliximab=2; Antibiotics=4; Not Reported=258	

BMI = Body Mass Index mHSS = modified Hidradenitis Suppurativa Score (Sartorius Score) NR = Not Reported SD = Standard Deviation Y = Yes N = No Ex = Ex Smoker

from the axillae (n=32, 43.8%) and groin (n=35, 48.0%), with a minority of samples being taken from the genital and perianal region (n=6, 8.2%). At the time of sampling patients were on treatment including Clindamycin+ Rifampicin (n=18); adalimumab (n=26); Metformin (n=2); levothyroxine (n=1); MABp1 (n=10); tetracyclines (n=12) Infliximab (n=2); other antibiotics (n=4). Treatment was not specified in 74 cases, with no treatment in 86 individuals and treatment withheld in 85 patients.

Only 5/19 (26.3%) studies analysed both lesional tissue and serum levels of cytokines, enabling direct comparison between these two compartments. 8/19 (42.1%) studies provided age and sex matched controls, 5/15 (33.3%) studies stratified by disease severity and no studies stratified by lesion site or comorbidities. 8/19 (42.1%) studies stratified or accounted for treatment or reported discontinuing treatment up to 3 weeks prior to sample collection (Table 3).

Cytokine analysis

A total of 81 discrete cytokines were analysed over the 19 studies (presented in Table 4). 6 studies provided a total of 78 outcomes from tissue of lesional or peri-lesional biopsies, 4 studies provided a total of 30 results from serum analysis and 1 study provided 15 results from exudate analysis. The remaining 8 studies did not provide quantification of cytokine levels but did provide analysis of the change and significance between lesion and control samples. The degree of change between lesional and control samples varied widely from 1.5 times the control level (IL-1RA $p=0.0112$) to 149 times the control level (IL-17 $p<0.05$). 33 cytokines were evaluated in more than one study. Only IL-1 β , IL-6, IL-8, IL-17A and TNF- α had data from 5 or more separate studies.

Cytokines and inflammatory proteins which were elevated in more than one study in lesional tissue included IL-1 β , IL-6R, IL-10, IL-17A, IL-36 α , IL-36 β , IL-36 γ , IL-36RA, TNF- α , sTNFR2, hBD1, hBD2, hBD3, s100A7, LL37/Cathelicidin, CCL3, CCL5, CCL27 and BLC. Cytokines and inflammatory proteins elevated in peri-lesional tissue included IL-1 β , IL-17, IL-36 β , IL-36RA, IL-37, IL-38 and TNF- α . IL-37 was the only cytokine identified which showed significant differences between lesional and peri-lesional tissue, with a 1.81 times elevation in lesional compared to peri-lesional tissue ($p=0.0002$)³. IL-17 was elevated in unaffected HS tissue compared to control patient tissue ($p<0.05$) in one study³¹. In HS tissue, S100A9, hBD1 and hBD2 were reduced but this data did not meet statistical significance. Two studies measuring IL-1 β levels showed no statistically significant difference between lesional and control skin^{7,25}. No significant elevation of IL-6 was seen in lesional tissue compared to control with the exception of 1 study²⁵. IL-8 levels only just made significance in two studies^{5,7}, with one study showing significant elevation of IL-8 in lesional compared to control tissue²⁴. Two additional studies showed no significant difference^{4,8}. TNF- α levels were significantly elevated compared to control tissue in two studies^{7,31} but not significantly in 2 additional studies^{4,24}. sTNFR1 was significantly elevated in one study²⁶ whilst showing a non-significant difference in a second

study²⁵. CCL5 was significant in 2 studies in lesional tissue compared with controls^{4,26}. One methodology using muramyl dipeptide (MDP) did not reach statistical significance compared to stimulation with Pam2CSK4 Lipopeptide, and non-treated (NT) cells. IFN- γ was elevated in lesional tissue with no significance in one study²⁸ and significance in another⁴.

Elevated cytokines and inflammatory proteins in HS serum included IL-1 β , IL-6, IL-8, IL-10, IL-12p70, IL-17, TNF- α , sTNFR1, CRP, ESR, LC2, and MMP2. TNF- β , and IFN- γ were elevated in wound exudate from active HS lesions. IFN- γ was noted to be decreased in HS patient serum compared to healthy control serum, despite the elevation in wound exudate. Conflicting results were seen in serum findings in IL-10, IL-17 and IFN- γ . One study demonstrated elevated serum IL-10 levels compared to control⁵ whereas two other studies^{8,27} showed no significant difference. Whilst two studies^{4,5} illustrated elevated IL-17 Serum levels in HS patients, one study⁷ showed no significant difference between patients and controls. IFN- γ showed no statistically significant decrease in the serum of HS patients compared to control in one study⁹ but a significant difference in a larger, higher powered study⁴.

Because adalimumab improves HS through TNF antagonism^{1,2}, this cytokine must be classified as pathogenic. TNF mediates inflammation in a classic “sepsis” cascade in tissues—in this pathway LPS from gram negative bacteria activates TNF release from cells, and then TNF stimulates production of IL-1 β , IL-6, and IL-8, leading to neutrophil attraction into sites of infection^{2,4}. Increases in IL-1 β and IL-8 measured in HS, as well as neutrophil accumulation, could result from this pathway. Alternatively, in psoriasis, TNF is a major cytokine that acts on the IL-23/Type 17 T-cell pathway at two points. First TNF induces IL-23 synthesis in myeloid (CD11c+) dendritic cells in the skin³⁴. Second, TNF (as well as other cytokines that also activate NF- κ B) act synergistically with IL-17A or IL-17F to increase synthesis of many other cytokines, chemokines, and inflammatory molecules in keratinocytes and other cell types. There are several clues that an IL-23/Type17 T-cell pathway may be active in HS which include detection of T_h17 T-cells in skin infiltrates, increased production of IL-17A, and increased production of LL-37/cathelicidin, S100A7, S100A8, S100A9, LCN2, IL-8, beta-defensins and IL-36; which are all molecules induced by IL-17 in keratinocytes, as also the presence of psoriasis-like epidermal hyperplasia in some reports. The increased production of CCL20⁴, would be predicted to increase tissue infiltration of both T_h17 T-cells and CD11c+ DCs, which have both been observed in HS, and increased production of TGF- β could increase differentiation of T_h17 T-cells from precursors and/or influence scarring in skin lesions. If IL-17 is driving inflammation in HS, one would expect to see increased production of additional chemokines that regulate neutrophil chemoattraction (CXCL1, CXCL2, CXCL3). Epidermal hyperplasia is not presently explained in HS, but this could be related potentially to increased expression of IL-19, IL-20 or IL-22, which are associated with the IL-23/Type 17 T-cell axis. If IL-22 is produced in HS lesions, this would implicate T_h22 T-cells as a T-cell type also associated with the IL-23/Type 17

Table 3. Critical evaluation of methodology of studies included in this review.

Cytokines Measured	Number of HS Patients	Number of Controls	Samples Analyzed	Age/Sex Matched Controls	Timing of Samples	Stratified by severity	Stratified by lesion site	Stratified by Co-morbidities	Stratified by Treatment	Sample Storage Time	Sample Types	Study Reference
IL-17 IL-22 IFNg IL-2 IL-10 GM-CSF	17	9	L, PL, U, C, S	Y	NR	NR	N	N	Y	NR	Skin, Serum	2
S100A7 Lysozyme LL37 hBD3 α-MSH MIF TNF-α IL-8 MHC1	18	12	L	N	NR	NR	N	N	N	NR	Skin	24
IL-36α IL-36β IL-36g	15	15	L, PL	NR	NR	NR	N	N	N	NR	Skin	3
IL-17 IL-22 IFNg CCL20 CCL27 S100A7 S100A8 IL-1B CCL5 IP10 IL-8 IL-6 TNF-α	18	18	L, PL, S	Y	NR	Y	N	N	N	NR	Skin, Serum	4
LL37 IL-17 TNF-α IL-23 IL-1b IL-10 IL-32	24	9	L	Y	NR	NR	NR	N	Y (untreated)	NR	Skin	7
IL-6 IL-23 TNF-α R1 IL-1β IL-8 IL-10 IL-12p70 IL17A TNFR2 CRP ESR	74	22	Serum only	N	NR	Y	NR	N	N	NR	Serum	8
IFNg, IL-12p70, IL-1β IL-1α IL-17A IL-6 TNF-α TNF-β IL-16 IL-12/23p40 IL-10 IL-4 IL-13 IL-2 IL-15 IL-7 IL-5 GM-CSF VEGF	8	8	Wound Exudate	Y	NR	N	N	N	N	NR	Wound Exudate	6
IL-1B IL-6 IL-8 IL-10 IL-17A IL-23 TNFR1 TNFR2	19	19	Serum only	N	Y (Fasting)	N	N	N	Y (Adalimumab)	NR	Serum only	25
TNF-α, IL-1B, IL-6 IL-10 IL-17 IL-22 IL-1RA	120	24	Serum and Pus	Y	N	Y	N	N	Y (Etanercept)	NR	Serum Pus	5
IL-17 IL-1B IL-10 TNF-α	44	5	L, PL, U	N	N	N	N	N	N	NR	Skin	31
IL-17 Caspase1 NLRP3 S100A8 S100A9	22	Yes (NR)	L, PL, U, C	NR	NR	N	N	N	N	NR	Skin	30
TNF-α IL-1β IL-6 IFNg IL-17A IL-22 IL1-2p70 IL-23p19 IL-17	3	(Unknown)	S	Y	NR	N	N	N	N	NR	Serum	9
IL-32 IL-32α IL-32β IL-32d IL-32g IFNg IL-17 IL-13	10	8	L, C	N	NR	N	N	N	Y (ceased 3/25 prior)	NR	Skin	32
IL-36α IL-36β IL-36g IL-36RA	25	10	L, C, S	N	NR	Y	N	N	Y (ceased 8/52 prior)	NR	Skin, Serum	29
TNF-α IFNg IL-1β IL-6 IL-10 IL-19, IL-17A IL-22 IL-36b IL-12/23p40 IL-22 E Selectin P Selectin CXCL6 CXCL11 CX3CL1 CCL2 CCL18 CXCL9 sVEGFR1 MMP2 Cystatin C LCN2	10	16	L	Y	NR	N	N	N	Y (ceased 3/25 prior)	NR	Skin Serum	28
IL-1β IL-2 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12p70 TNF-α IFNg	20	6	L, PL, C	N	NR	Y	N	N	N	NR	Skin	26
IL-1α, IL-8	10	10	S	N	NR	N	N	N	Y	NR	Serum	33

Table 2. Critical Evaluation of Methodology of Studies Included in This Review Key: L= Lesional, PL= Perilesional, U= Uninvolved, C= Control S=Serum, Y=Yes, N=No, NR= Not Reported.

Table 4. Reported cytokine results of studies included in this systematic review.

Target Cytokine	Mean Level in Patient Serum (pg/mL)	Mean Level in Control Serum (pg/mL)	Mean Level in Lesional Tissue (pg/mL)	Mean Level in Perilesional Tissue (pg/mL)	Mean Uninvolved Tissue Levels (pg/mL)	Mean Control Tissue Levels (pg/mL)	Fold Increase	Comparison and Significance	Comparison and Significance	Study Reference
IL-1 α			1126			2549		Le:Ce P=0.53		6
			0.2			0.1	NR	L:C NS		26
IL-1RA		697.2						HSs:Cs NS		33
			44.0			29.6	1.5	L:C P=0.0112		26
IL-1 β	0.9	0.4						HSs:Cs P=0.801		8
			862.5			1503		Le:Ce P=0.69		6
								L:C NS	Lpa:C NS	25
				SERUM ONLY				HSs:Cs P=0.044		5
			100	10	3	1	115 fold	L:C P=0.001	PL:C 0.05	31
							R=0.7 [#]	L:U P=0.01	U:C NS	7
IL-4			1.6			0.0	54.4	L:C P=0.0028		26
			6.56			9.77		Le:Ce P=0.54		6
IL-5			0.0			0.1		L:C NS		7
			0.2			0.2		L:C NS		7
IL-6			30.15			9.314		Le:Ce P=0.17		6
								L:C* NS L:C** NS L:C*** NS		4
	6.2	0.6						HSs:Cs P=0.001		8
			2377			5451		Le:Ce NS		6
sIL-6R				SERUM ONLY				L:C P=0.05	Lpa:C 0.05	25
			124.4		101.9			HSs:Cs***		5
			16.3			4.4	3.7	L:C NS		7
								L:C P=0.0028		7

Target Cytokine	Mean Level in Patient Serum (pg/mL)	Mean Level in Control Serum (pg/mL)	Mean Level in Lesional Tissue (pg/mL)	Mean Level in Perilesional Tissue (pg/mL)	Mean Uninvolved Tissue Levels (pg/mL)	Mean Control Tissue Levels (pg/mL)	Fold Increase	Comparison and Significance	Comparison and Significance	Study Reference
IL-8	NR	NR	i69.6 / s67.6			64.9		Li:C P<0.01	Ls:C P<0.001	24
								Li:C* NS		4
								Li:C** NS		
								Li:C*** NS		
IL-10	27.9	36.3						HSSs:Cs NS		8
								L:C P= 0.05	Lpa:C NS	25
			1401			12.0		L:C NS		7
	1000	3000						L:C P= 0.049		33
	3.4	3.3						L:C P<0.05		4
			19.85			34.74		HSSs:Cs NS		8
IL-11								Le:Ce NS		6
								L:C P= 0.05	Lpa:C 0.05	25
					SERUM ONLY			HSSs:Cs+ P= 0.0001		5
					SERUM ONLY			HSSs:Cs** P= 0.0001		5
			3.8	1.1		0.4		L:C P= 0.01	PL:C NS	31
	3	2						L:U P= 0.01	U:C NR	
IL-12p40								HSSs:Cs NS		27
			19.2			1.3	14.8	L:C P= 0.0028		7
			78.6			7.2	11.0	L:C P= 0.0056		7
			488.3			97.86		Le:Ce P= 0.07		6
IL-12p70		75						HSSs:Cs NS		27
			0.5			0.4		L:C NS		7
	3.4	0.6	9.412			15.02		HSSs:Cs P= 0.427		8
IL-13			0.0			0.0		Le:Ce P= 0.609		6
			70.98			55.61		L:C NS		7
			0.0			0.1		Le:Ce P= 0.56		6
							L:C NS		7	

Target Cytokine	Mean Level in Patient Serum (pg/mL)	Mean Level in Control Serum (pg/mL)	Mean Level in Lesional Tissue (pg/mL)	Mean Level in Perilesional Tissue (pg/mL)	Mean Uninvolved Tissue Levels (pg/mL)	Mean Control Tissue Levels (pg/mL)	Fold Increase	Comparison and Significance	Comparison and Significance	Study Reference	
IL-15			24.5			5.61		Le:Ce P= 0.18		6	
			1.9			2.9		L:C NS		7	
			15277			15586		Le:Ce P= 0.97		6	
			22.3			4.2	5.3	L:C P= 0.0028		7	
IL-17								S:C P<0.005		4	
				SERUM ONLY		SERUM ONLY		HSs:Cs+	0.014	5	
				SERUM ONLY		SERUM ONLY		HSs:Cs++	0.005	5	
			150	45	1	1	149 fold	L:C P= 0.05	PL:C 0.05	31	
IL-17A								L:PL NS	U:C 0.05		
	5.6	0.3						L:C ↑(NS)	L:PL No Diff	30	
										27	
										4	
IL-22			1006			32.7		HSs:Cs NS		8	
								Le:Ce NS		6	
	4	5						L:C P= 0.05	Lpa:C NS	25	
			8.1	NR		1.1	7.3	HSs:Cs NS		27	
IL-23								L:C P= 0.0056		26	
								L:C NS		4	
	8.8	0.0						HSs:Cs NS		8	
								L:C NS	Lpa:C 0.05	25	
IL-32	50ng/mL	1ng/mL	Only Normalised Values Provided								7
								R=0.68*			
IL-32α							4 (skin)	L:C P= 0.01	HSs:Cs	29	
IL-32β							50 (serum)				
IL-32g							3 fold	L:C P= 0.01		29	
							2 fold	L:C P= 0.05		29	
IL-32d							Not elevated	L:C P= 0.001		29	
							3 fold	L:C NS		29	

Target Cytokine	Mean Level in Patient Serum (pg/mL)	Mean Level in Control Serum (pg/mL)	Mean Level in Lesional Tissue (pg/mL)	Mean Level in Perilesional Tissue (pg/mL)	Mean Uninvolved Tissue Levels (pg/mL)	Mean Control Tissue Levels (pg/mL)	Fold Increase	Comparison and Significance	Comparison and Significance	Study Reference
IL-36α			0.4	0.02		0.02		L:C P=0.0174	PL:C NS	3
	250	0				1	45.07 fold	L:C P= 0.01		28
IL-36b			4.33	3.00		0.51		L:C P= 0.0001	PL:C 0.0035	3
	15	4				1	1.45 fold	L:C P= 0.25		28
IL-36g			3.64	0.83		0.49		L:C P= 0.0161	PL:L 0.0302	3
	100	20				1	1.96 fold	L:C P= 0.07		28
IL-36RA			0.46	0.28		0.06		L:C P= 0.0001	PL:C 0.0003	3
	50	100	No Quantification				No Increase	L:C P= 0.10		28
IL-37			3.24	14.7		1.81		PL:L P= 0.0002	PL:C 0.0001	3
IL-38			0.09	0.19		0.06		L:C P= 0.0230	PL:C 0.0069	3
			169.4	NR		65.8	NR	L:C NS	Ls:C NS	24
TNF-α								L:C* NS		4
								L:C** NS		
								L:C*** NS		
							Le:Ce P= 0.7			6
			SERUM ONLY	SERUM ONLY				HSS:Cs* P=0.021		5
TNF-β			2.2	1.3	0.6	0.7		L:C P=0.01	PL:C 0.01	31
								L:PL NS	U:C NS	
			0.3			0.2	1.6	L:C P=0.0336		26
sTNFR1			9.24			1.65		Le:Ce P=0.03		6
			0.4			0.4	NR	L:C NS		26
sTNFR1	879.8	325.9						HSS:Cs P <0.001		8
								L:C NS	Lpa:C 0.05	25
			78.0			40.2	1.9	L:C P= 0.0112		26

Target Cytokine	Mean Level in Patient Serum (pg/mL)	Mean Level in Control Serum (pg/mL)	Mean Level in Lesional Tissue (pg/mL)	Mean Level in Perilesional Tissue (pg/mL)	Mean Uninvolved Tissue Levels (pg/mL)	Mean Control Tissue Levels (pg/mL)	Fold Increase	Comparison and Significance	Comparison and Significance	Study Reference
sTNFR2	927.9	527.4						HSs:Cs P= 0.053		8
								L:C P= 0.05	Lpa:C 0.05	25
hBD1			47.0			8.1	5.8	L:C P= 0.0028		26
			0.019 0.021 0.018			0.058 0.077 0.095	0.3 0.3 0.2	L:C* P= 0.240 L:C** P= 0.132 L:C*** P= 0.026		4
hBD2			0.013 0.019 0.058			0.011 0.018 0.067	1.1 1.1 0.9	L:C* P= 0.937 >L:C** P= 0.699 L:C*** P= 0.937		4
			76.9 ^s			72.5	NR	L:C P<0.05	Ls:C NS	24
S100A7			0.33 0.33 0.379			0.117 0.125 0.203	2.8 2.6 1.9	L:C* P= 0.485 L:C** P= 0.394 L:C*** P= 0.485		4
			84.8	77.8 ^s		71.5	NR	L:C P<0.001	Ls:C P<0.05	24
S100A8			1.516 1.625 2.297			0.177 0.354 0.707	8.6 4.6 3.2	L:C* P= 0.009 L:C** P= 0.180 L:C*** P= 0.132		4
			24.251 25.992 24.251			4.925 11.314 10.556	4.9 2.3 2.3	L:C* P= 0.240 L:C** P= 0.537 L:C*** P= 0.393		4
S100A9			0.003 0.005 0.003			0.002 0.004 0.006	1.7 1.1 0.6	L:C P<0.001 L:C** P= 0.009 L:C*** P= 0.132	L:PL (↑(NS))	30
			84.1 / 80.9 ^s			75.8	NR	L:C NS L:C** NS L:C*** NS	Ls:C NS	24
Lysozyme			55.2 / 52.7 ^s			59.6		L:C NS	Ls:C P<0.05	24
MIF			77.8 / 77.8 ^s			70.7		L:C NS	Ls:C P<0.01	24
αMSH			NR	i74.6 / 73.1 ^s		NR	70.9	L:C P<0.01	Ls:C P<0.01	24
MHC1			75.5 / 74.7 ^s			74.4		L:C NS	Ls:C NS	24
RNase7			0.435 0.330 0.574			0.063 0.077 0.109	7.0 4.3 5.3	L:C* P= 0.145 L:C** P= 0.589 L:C*** P= 0.179		4
IP10			89.9			12.6		L:C* P<0.05 L:C** P<0.005 L:C*** P<0.05		4

Target Cytokine	Mean Level in Patient Serum (pg/mL)	Mean Level in Control Serum (pg/mL)	Mean Level in Lesional Tissue (pg/mL)	Mean Level in Perilesional Tissue (pg/mL)	Mean Uninvolved Tissue Levels (pg/mL)	Mean Control Tissue Levels (pg/mL)	Fold Increase	Comparison and Significance	Comparison and Significance	Study Reference
CCL3			0.4			0.2	2.0	L:C P= 0.0196		26
CCL5			-			-		L:C* P<0.05		4
			46.1			6.2		L:C** P<0.05		
			-			-		L:C*** NS		
CCL20			7.6			1.4	5.4	L:C P= 0.0112		26
								L:C P<0.005		
CCL27								L:C P<0.05		4
								L:C P<0.05		
CRP	13.4	1.2						HSs:Cs p<0.001		8
								L:C P= 0.05 Lpat:C 0.05		
ESR	29.5	10.2						HSs:Cs <0.001		25
								L:C P= 0.05 Lpat:C 0.05		
IFNg								L:C NS		7
								HSs:Cs ↑ (NS)		
								R=0.7 <5% Normal		
GMCSF			1418			102.5		Le:Ce P= 0.027		6
								HSs:Cs P<0.05 L:C P<0.05		
			78.45			82.13		Le:Ce P= 0.96		
VEGF			0.4			0.0	NR	L:C NS		26
			632.1			1544		Le:Ce P= 0.23		
sVEGFR1	60	60						HSs:Cs NS		6
Caspase 1						No Quanti	No Quanti	L:C ↑ (NS)		27
						No Quanti	No Quanti	L:C ↑ (NS)	L:PL ↑ (NS)	
NLRP3						No Quanti	No Quanti	L:C ↑ (NS)		30
						No Quanti	No Quanti	L:C ↑ (NS)	L:PL NS	
CAMP							4	L:C NS		7
Uteroglobulin	20	20						HSs:Cs NS		27
Cystatin C	0.85	0.8						HSs:Cs		27
LCN2	90	40	0.5		0.02			HSs:Cs <0.001 L:C <0.001		27
BD2	0.9	1						HSs:Cs NS		27
MMP2	200	210						HSs:Cs <0.05		27
BLC			8.1			0.58	10.5	L:C P= 0.0056		26

Target Cytokine	Mean Level in Patient Serum (pg/mL)	Mean Level in Control Serum (pg/mL)	Mean Level in Lesional Tissue (pg/mL)	Mean Level in Perilesional Tissue (pg/mL)	Mean Uninvolved Tissue Levels (pg/mL)	Mean Control Tissue Levels (pg/mL)	Fold Increase	Comparison and Significance	Comparison and Significance	Study Reference
ICAM-1			98.7			31.9	3.1	L:C P= 0.0028		26
Eotaxin			0.1			0.1	NR	L:C NS		26
Eotaxin2			3.9			2.5	NR	L:C NS		26
CXCL6	160	140						NS		27
CXCL9			219.8			13.8	16	L:C P= 0.0028		26
CXCL11	0.4	0.4						NS		27
CX3CL1	0.9	1						NS		27
I-309			0.4			0.3	NR	L:C NS		26
MCP1			47.5			37.1	NR	L:C NS		26
M-CSF			0.4			0.2	NR	L:C NS		26
MIP1b			16.1			5.8	NR	L:C NS		26
MIP1d			0.1			0.1	NR	L:C NS		26
PDGF			0.5			0.2	NR	L:C NS		26
TIMP1			260.1			166.2	NR	L:C NS		26
TIMP2			989.2			997.3	NR	L:C NS		26

Key: L= Lesional ; PL= Perilesional; C= Control; NS= Not Significant ; HSs= HS Serum; HSe= HS Exudate; Ce= Control Exudate; I = Inflamed lesional skin, S= Scarred lesional skin, #= Vs cAMP * = NT (Non-Treated) Samples , ** = Stimulation by Pam2CSK4 Lipopeptide, *** = Stimulation by Muramyl Dipeptide (MDP), + Heat Killed Candida Albicans; ++ Heat Killed Staph Aureus, +++ Lipopolysaccharide;

T-cell axis. There is an uncertain role for other T-cell subsets in HS. Increased production of CXCL9 and IP-10 (CXCL10) are often linked to production of IFN- γ from T_h1 T-cells in inflammatory sites, but IL-26 or IL-29, which are also cytokines produced by T_h17 T-cells are alternative activators of STAT1 and CXCL9 production. IL-32 production in HS may also be linked to a T-cell subset that produces this cytokine. Low production of T_h2 associated cytokines (IL-4, IL-5, or IL-13) has been measured in HS, suggesting an unlikely role of this T-cell subset. Likewise, the presence and function of T regulatory cells (Tregs) in HS lesions needs further study. IL-10 which is elevated in HS could be produced by either Tregs or the cDC1 (BDCA3+) DC subset, but levels may be inadequate to control tissue inflammation. At present, dendritic cell subsets are also incompletely characterized in HS. Potential sources of IL-12 or IL-23 are CD11c+ DCs, which includes the tissue resident BDCA-1+ (cDC2) subset and less mature inflammatory DCs, which are abundant cells in inflammatory lesions of psoriasis or atopic dermatitis but have not been investigated in HS. Cytokine contributions by other cell types such as innate lymphoid cells, macrophages, mast cells, and other leukocytes also remains to be determined.

Cytokine analysis methods

The methodologies of cytokine analysis varied widely (Table 5). 92 results were produced using electrochemical luminescence (ECL) procedures from three separate systems and manufacturers. 62 results were produced using ELISA. 18 results⁴ were performed with either ELISA or ECL but not further specified. 15 results were produced using polymerase chain reaction (PCR) with three separate systems from three manufacturers. Four discrete cytokines (IL-10, IL-17, TNF- α and IFN- γ) were analysed using all three techniques (ECL, ELISA and PCR), whilst 15 discrete cytokines (IL-6, IL-8, IL12p40, IL-17A, IL-22, IL-23, S100A7, S100A8, S100A9, RNase7, IP-10, CCL5, CCL20, CCL27) were analysed using ELISA and ECL only. We note IL-17 levels may well be below the lower limit of quantification with ELC and ELISA based approaches, with only the Singulex platform having the ability to quantify levels of IL-17 present in blood and serum of normal subjects.

Assessment of bias

Assessment of bias is presented in Table 6. Two of the 14 questions regarding participation rate and loss to follow up were considered not applicable. All included studies identified clear objectives and a clearly defined study population. No clear inclusion or exclusion criteria were specified for 17 of the 19 studies. Power estimation was made for one study³³, and recording of all exposures (disease activity, comorbidities etc) were made prior to assessment of the outcomes (cytokine levels). The timeframe of analysis was sufficient to identify an association, but only 10 of the 19 studies (52.6%) documented different levels of exposures (disease severity, metabolic comorbidities, family history etc). There were no serial measures of cytokine levels in the majority of studies. Only three studies^{5,25,33}, examining cytokine levels after monoclonal antibody administration has measurements at two distinct time points. Outcomes of interest (cytokine levels) were measured consistently within

studies, however there was great variance in the methods of measurement and analysis between studies (Table 5). No studies took into account known confounding variables into analysis of their results by stratification or regression analyses.

Assessment of heterogeneity

36 of the 81 identified cytokines or inflammatory proteins were assessed by more than 1 study. 23 of those cytokines had raw data available. No studies had sufficient measures of spread in order to calculate I² measure of heterogeneity and so chi-squared statistic was used as an alternate marker of heterogeneity (Table 7) along with a funnel plot (Figure 3). In total, 18 individual cytokines (78.2%) were found to demonstrate heterogeneity. Only eight cytokines (Serum IL-10, Lesional IL-1 α , IL-12p70, hBD1, hBD2, hBD3, S100A9 and GM-CSF) illustrated homogeneity. Due to this high level of heterogeneity and concerns regarding the methodological quality of included studies, meta-analysis was not deemed appropriate to perform.

Discussion

The overall quality of reporting in the identified studies was low with little consistency between methodologies and cytokines examined. There was also great variability in the ages, genders, comorbidities, associated conditions and treatments of the patients included in these studies. This was again reflected in the high number of cytokines with statistical heterogeneity (Table 7). The studies presenting conflicting data are often those studies with lower numbers of patients as well as lack of matched controls and/or lack of stratification by treatment. Meta-analysis using individual patient data would be required in order to account for these factors and re-assess the relationship between lesional and control cytokine levels.

In assessing the relationship between lesional and peri-lesional tissue, it has been demonstrated by many authors that different cytokines are present in peri-lesional tissue as opposed to lesional tissue. The definition of peri-lesional tissue is fairly consistent in the studies examined being 2cm from an active HS nodule on unaffected skin. However, no studies reported ultrasound examination of the peri-lesional skin to ensure that sub-clinical extension of the adjacent nodule (either in the dermis or the subcutaneous tissue) was being inadvertently sampled. This is an important differentiation to make in terms of identifying the subclinical pathogenic processes that precipitate this disease.

The raw data collated illustrates a number of paradoxically elevated levels of control cytokines (IL-15, IL-16) (Table 4). Many of these control readings lie near the lower detection limit of specific assays in individual papers, and thus the possibility of erroneously elevated control readings cannot be excluded. The wide interquartile ranges of studies which did report individual patient data⁷, suggest that analyzing aggregate data is not optimal and is prone to misrepresentation of the relationship between clinical disease, comorbidities and cytokine levels. Furthermore, high levels of heterogeneity within the measurements of individual cytokines suggest that examination of and correction for other variables or confounders is required.

Table 5. Cytokine analysis methodology of studies included in this review.

Cytokine	Method	Details	Study
IL-1 α	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6
IL-1 α	ECL	(CBA Human Inflammation kit and CBA Human TH17H2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analysis: FACSCalibur (BD Biosciences)	26
	ECL	(CBA Human Inflammation kit and CBA Human TH17H2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analysis: FACSCalibur (BD Biosciences)	26
IL-1 β	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	8
	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6
	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	25
	ELISA	Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).	5
	PCR	IL10, IL17A, IL18, IL18 and NLRP3 was performed with predesigned Taqman gene expression assays (Applied Biosystems) on a Roche Light Cycler (Roche, Pleasanton, CA, U.S.A.)	31
	PCR	(Hs01555410_m1), ABI-Prism 7300 Sequence Detector System (Applied Biosystems)	7
IL-4	ECL	(CBA Human Inflammation kit and CBA Human TH17H2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analysis: FACSCalibur (BD Biosciences)	26
	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6
IL-5	ECL	(CBA Human Inflammation kit and CBA Human TH17H2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analysis: FACSCalibur (BD Biosciences)	7
	ECL	(CBA Human Inflammation kit and CBA Human TH17H2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analysis: FACSCalibur (BD Biosciences)	7
	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6
IL-6	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	8
	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6
IL-8	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA). The Milliplex MAP multiplex assay	25
	ELISA	Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).	5
sIL-6R	ECL	(CBA Human Inflammation kit and CBA Human TH17H2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analysis: FACSCalibur (BD Biosciences)	7
	ECL	(CBA Human Inflammation kit and CBA Human TH17H2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analysis: FACSCalibur (BD Biosciences)	7
IL-8	ELISA	pABG AHC0881 1:50 rabbit antihuman	24
	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	8
	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	25
IL-10	ECL	(CBA Human Inflammation kit and CBA Human TH17H2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analysis: FACSCalibur (BD Biosciences)	7
	ELISA	Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).	33
IL-10	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	8
	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6

Cytokine	Method	Details	Study
	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	25
	ELISA	Cytokines were measured in duplicate by ELISA (R&D Minneap-olis, USA).	5
	ELISA	Cytokines were measured in duplicate by ELISA (R&D Minneap-olis, USA).	5
	PCR	IL10, IL17A, IL18 and NLRP3 was performed with predesigned Taqman gene expression assays (Applied Biosystems) on a Roche Light Cycler (Roche, Pleasanton, CA, U.S.A.)	31
	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	7
IL-11	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	7
IL-12p40	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1)	6
	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	7
IL-12p70	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	8
	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1)	6
	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	7
IL-13	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1)	6
	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	7
IL-15	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1)	6
	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	7
IL-16	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1)	6
	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	7
IL-17	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
	ELISA	Cytokines were measured in duplicate by ELISA (R&D Minneap-olis, USA).	5
	PCR	IL10, IL17A, IL18 and NLRP3 was performed with predesigned Taqman gene expression assays (Applied Biosystems) on a Roche Light Cycler (Roche, Pleasanton, CA, U.S.A.)	31
	PCR	IL-17 (clone AF-317-NA; R&D Systems, Wiesbaden, Germany).	30
	PCR	IL-17 (Hs00174383_m1), ABI-Prism 7300 Sequence Detector System	27
IL-17A	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA). eBioscience, Paris, France	4
	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	8
	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1)	6
	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	25
	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26

Cytokine	Method	Details	Study
IL-22	ELISA	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA). eBioscience, Paris, France	4
IL-23	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	8
	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	25
IL-32	PCR	(Hs00992441_m1) ABI-Prism 7300 Sequence Detector System (Applied Biosystems)	7
	PCR	IL-32 (Hs00992441_m1), ABI-Prism 7300 Sequence Detector System	29
IL-32α	PCR	IL-32a (Hs04353657_gH), ABI-Prism 7300 Sequence Detector System	29
IL-32β	PCR	IL-32b (Hs04353658_gH), ABI-Prism 7300 Sequence Detector System	29
IL-32g	PCR	IL-32c (Hs04353656_g1), ABI-Prism 7300 Sequence Detector System	29
IL-32d	PCR	IL-32d (Hs04353659_gH), ABI-Prism 7300 Sequence Detector System	29
IL-36α	ELISA	Rabbit polyclonal anti-IL-36a (C-terminal; ab180909), from Abcam, Cambridge, U.K. at 1 : 500 dilution.	3
IL-36β	ELISA	IL-36a AF1078, RnD	28
	ELISA	Rabbit polyclonal anti- IL-36b (C-terminal; ab180890) from Abcam, Cambridge, U.K. at 1 : 500 dilution.	3
IL-36g	ELISA	AF1099, RnD	28
	ELISA	Mouse monoclonal anti-IL-36c ab156783; (Abcam, Cambridge, U.K.) at 1 : 500 dilution.	3
IL-36RA	ELISA	AF2320, RnD	28
	ELISA	Rabbit polyclonal from Abcam, Cambridge, U.K. at 1 : 500 dilution.	3
IL-37	ELISA	AF1275, RnD	28
	ELISA	Rabbit polyclonal Abcam, Cambridge, U.K. at 1 : 500 dilution.	3
IL-38	ELISA	Rabbit polyclonal Abcam, Cambridge, U.K. at 1 : 500 dilution.	3
TNF-α	ELISA	TNF-alpha: 559071 mABG 1:10 mouse antihuman	24
	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
TNF-β	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6
	ELISA	Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).	5
sTNFR1	PCR	Taqman gene expression assays (Applied Biosystems) on a Roche Light Cycler	31
	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
sTNFR2	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6
	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
sTNFR2	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	8
	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	25
hBD1	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
	ELISA/ ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	8
hBD1	ECL	xMAP technology (Luminex Corporation, Austin, TX, USA)	25
	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
hBD1	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4

Cytokine	Method	Details	Study
hBD2	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
hBD3	ELISA	ELISA 1 : 400; rabbit antihuman	24
	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
S100A7	ELISA	Psoriasis HL15-4 mAbG 1:20,000 mouse antihuman	24
	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
S100A8	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
	ELISA	S100A8 and S100A9 (monospecific affinity-purified rabbit antiserum to S100A8 and to S100A9	30
S100A9	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
	ELISA	S100A8 and S100A9 (monospecific affinity-purified rabbit antiserum to S100A8 and to S100A9	30
LL37	ELISA	Cathelicidin ab64892 pAbG 1:1000 rabbit antihuman	24
Lysozyme	ELISA	Lysozyme A0099 pAbG 1:100 rabbit antihuman	24
MIF	ELISA	MIF MAB289 mAbG 1:100 mouse antihuman	24
αMSH	ELISA	alpha MSH M09393 mAbG 1:500 rabbit antihuman	24
MHC1	ELISA	MHC1 W6/32 mAbG 1:50 mouse antihuman	24
RNase7	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
IP10	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
CCL3	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
CCL5	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
CCL20	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
CCL27	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
CRP	ECL	xMAP luminex Luminex Corporation, Austin, TX, USA	8
	ECL	xMAP luminex Luminex Corporation, Austin, TX, USA	25
ESR	ECL	xMAP luminex Luminex Corporation, Austin, TX, USA	8
	ECL	xMAP luminex Luminex Corporation, Austin, TX, USA	25
IFNγ	PCR	(Hs00174143_m1), ABI-Prism 7300 Sequence Detector System (Applied Biosystems)	7
	ELISA	ELISA kits from Sanquin (Amsterdam, The Netherlands)	9
	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6

Cytokine	Method	Details	Study
	ELISA/ ECL	ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).	4
GM-CSF	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD) MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6
	ELISA	Quantibody Human Inflammation array 3 (RayBiotech Inc., Norcross, GA, U.S.A.).	26
VEGF	ECL	Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD) MSD V-Plex cytokine panel 1 and the V-plex proinflammatory panel 1	6
sVEGFR1	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
Caspase 1	ELISA	Kelly <i>et al.</i> Caspase-1 fluorochrome inhibitor of caspases (FLICA) (ImmunoChemistry Technologies, Bloomington, MN, U.S.A.).	30
NLRP3	PCR	Kelly IL10, IL17A, IL1B, IL18 and NLRP3 was performed with predesigned Taqman gene expression assays (Applied Biosystems) on a Roche Light Cycler (Pleasanton, CA, U.S.A.)	30
CAMP	PCR	(Hs00189038_m1) ABI-Prism 7300 Sequence Detector System (Applied Biosystems)	7
Uteroglobin	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
Cystatin C	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
LCN2	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
BD2	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
MMP2	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
BLC	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
ICAM-1	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
Eotaxin	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
Eotaxin2	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
CXCL6	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
CXCL9	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
CXCL11	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
CX3CL1	ELISA	Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne	27
I-309	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
MCP1	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
M-CSF	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
MIP1b	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
MIP1d	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
PDGF-BB	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
TIMP1	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26
TIMP2	ECL	(CBA Human Inflammation kit and CBA Human TH1/TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)	26

Table 4: Antibodies Used for Identification of Cytokines in Studies Included in this Systematic Review. ECL: Electrochemiluminescence

Table 6. Risk of bias across studies included in this review.

Study Reference	1. Was the research question or objective in this paper clearly stated?	2. Was the study population clearly specified and defined?	3. Was the participation rate of eligible persons at least 50%?	. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	5. Was a sample size justification, power description, or variance and effect estimates provided?	6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	8. For exposures that vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	10. Was the exposure(s) assessed more than once over time?	11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	12. Were the outcome assessors blinded to the exposure status of participants?	13. Was loss to follow-up after baseline 20% or less?	14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?
Moran <i>et al.</i> ²	Y	Y	N/A	N	N	Y	Y	Y	N	N	Y	NR	N/A	N
Emelianov <i>et al.</i> ²⁴	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Hessam <i>et al.</i> ³	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Hotz <i>et al.</i> ⁴	Y	Y	N/A	N	N	Y	Y	Y	Y	N	Y	NR	N/A	N
Thomi <i>et al.</i> ⁷	Y	Y	N/A	N	N	Y	Y	Y	Y	N	Y	NR	N/A	N
Jimenez-Gallo <i>et al.</i> ⁵	Y	Y	N/A	N	N	Y	Y	Y	Y	N	Y	NR	N/A	N
Banerjee <i>et al.</i> ⁶	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Jimenez-Gallo <i>et al.</i> ²⁵	Y	Y	N/A	Y	N	Y	Y	N	Y	N	Y	NR	N/A	N

Study Reference	1. Was the research question or objective in this paper clearly stated?	2. Was the study population clearly specified and defined?	3. Was the participation rate of eligible persons at least 50%?	. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	5. Was a sample size justification, power description, or variance and effect estimates provided?	6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	10. Was the exposure(s) assessed more than once over time?	11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	12. Were the outcome assessors blinded to the exposure status of participants?	13. Was loss to follow-up after baseline 20% or less?	14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?
Kanni <i>et al.</i> ⁵	Y	Y	N/A	N	N	Y	Y	Y	Y	Y	Y	NR	N/A	N
Kelly <i>et al.</i> ³¹	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Lima <i>et al.</i> ³⁰	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Ten Oever <i>et al.</i> ⁹	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Schlappbach <i>et al.</i> ³²	Y	Y	N/A	N	N	Y	Y	Y	Y	N	Y	NR	N/A	N
Thomi <i>et al.</i> ²⁹	Y	Y	N/A	N	N	Y	Y	Y	Y	N	Y	NR	N/A	N
Thomi <i>et al.</i> ²⁸	Y	Y	N/A	N	N	Y	Y	Y	Y	N	Y	NR	N/A	N
Wolk <i>et al.</i> ²⁷	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Van der Zee <i>et al.</i> ²⁶	Y	Y	N/A	N	N	Y	Y	Y	Y	N	Y	NR	N/A	N
Kanni <i>et al.</i> ³³	Y	Y	N/A	Y	Y	Y	Y	Y	Y	N	Y	NR	N/A	N

Key: Y = Yes; N= No; NR= Not Reported N/A = Not Applicable

Table 7. Table of heterogeneity of cytokine studies by chi-squared tests for homogeneity.

Cytokine	Chi Squared	P
IL1a Lesional	0.3525	p=0.552705
IL1b Lesional	153.5947	p<0.00001
IL4 Lesional	4.3992	P=0.035955
IL5 Lesional	15.1692	P=0.000098
IL6 Lesional	461.9724	P<0.00001
IL8 Lesion	846.6251	P<0.0001
IL8 Serum	94.4212	P<0.0001
IL10 Lesion	90.3211	P<0.0001
IL10 Serum	0.1595	P=0.689624
IL12p40 Lesional	4.9618	P=0.025913
IL12p70 Lesional	2.2116	P=0.136973
IL13 Lesional	5.4163	P=0.019949
IL15 Lesional	39.2837	P<0.00001
IL16 Lesional	126.1959	P<0.00001
IL17A Lesional	22.6668	P<0.00001
IL17A Serum	19.1621	P=0.000012
TNFa Lesional	6.9761	P=0.030561
TNFb Lesional	7.4004	P=0.006521
hBD1 Lesional	2.3317	P=0.311656
hBD2 Lesional	0.6488	P=0.722954
hBD3 Lesional	1.0314	P=0.597084
S100A7 Lesional	621.2537	P<0.00001
S100A8 Lesional	19.6371	P=0.000054
S100A9 Lesional	1.27	P=0.529927
RNAse 7	6.7263	P=0.034626
GMCSF Lesional	1.9405	P=0.163611

Methodological quality

Regarding methods of cytokine analysis, a number of authors have identified variability in cytokine levels measured with different forms of multiplex assays as well as traditional ELISA methods³⁵⁻³⁹. Different methods of cytokine analysis are known to be prone to variability, with some cytokines more sensitive than others. For example, IFN- γ and IL-1 β were overestimated compared with ELISA methods³⁷, whilst IL-6 levels were underestimated³⁷. IL-6 levels when compared across four different multiplex assays showed significant variation in detectable range, accuracy and responsiveness³⁶. The correlation of TNF- α between ELISA and Multiplex assays was also poor ($r=0.31$)³⁶. Issues also exist with minimum detectable levels of cytokines with specific bead-based arrays³⁶. As an example, minimal detectable dose readings reported for IL-12p70 using some multiplex arrays³⁹ are higher than the levels reported in lesional HS samples⁶. Therefore, whilst the general trends in the level of

consistently elevated or suppressed cytokines in HS are reliable, the quantification of individual cytokines as well as the relationship between comorbidities and cytokine levels requires further research with consistent, reliable and accurate methodologies in order to further dissect the inflammatory cascade in this disease.

Keratinocyte mediated inflammatory pathways

The majority of elevated cytokines and inflammatory proteins identified in lesional skin of HS (TNF- α , IL-1 β , IL-6, IL-8, IL-11, IL-23, IL-17A, IL-33, IL-36, LL-37, S100A7, S100A8, S100A9, GM-CSF, TGF- β , hBD2, hBD3, CCL3, CXCL9, CXCL11, PDGF, CCL5, CCL-20, MIF, GM-CSF and LCN2) are those known to be produced by keratinocytes, as well as perpetuating a self-amplification pathway³⁴ (Figure 2). Additionally T-cells produce IL-17A, IL-17F, IL-26, IL-29, and IFN- γ ; dendritic cells produce IL-12, IL-23 and possibly IL-39; neutrophils produce S100A8




Figure 2. Inflammatory pathways in hidradenitis suppurativa, a schematic representation of the results identified in this systematic review. Immunological ‘priming’ occurs due to the contribution of adipose tissue, genetic susceptibility, smoking-related inflammatory mediators and obesity related pro-inflammatory signals and the composition of the microbiome. Increased activity of cDC1, cDC2 and T cells lead to both keratinocyte hyperplasia via the actions of IL-12 and IL-23, as well as a Th17 predominant immune response. Alterations of antimicrobial peptides (AMPs) also occur throughout the epidermis. The dermal inflammation interacting with the hyperplastic epidermis result leads to a self-perpetuating inflammatory feed forward mechanism mediated by IL-36, IL-1B and TNF-α. The development of scarring and sinus tracts is associated with MMP2, ICAM-1 and TGF-Beta, with possible augmentation of ICAM-1 and TGF-B signaling via specific components of the microbiome. TNF-α, PGE2 and CXCL2 then lead to additional feed forward mechanisms perpetuating the inflammatory cycle.




Figure 3. Funnel plot of selected cytokine in lesional and control samples of hidradenitis suppurativa. IL-1a = Red, IL-10 = Blue, IL-12p70 = Green, hBD1 = Purple, hBD2 = light purple, hBD3 = Black, S100A9 = White, GMCSF = Yellow.

and S100A9 (calgranulin); and innate lymphoid cells also contribute IFN- γ , IL-17A and IL-17F. This inflammatory model has been well documented and explored in both psoriasis and atopic dermatitis^{34,40}. The psoriasiform epidermal hyperplasia seen in HS (mediated by IL-17 and maintained by IL-23-mediated T_H17 stimulation)³⁴ reflects this common inflammatory pathway.

The other elevated non-keratinocyte produced cytokines in HS (IL-4, IL-5, IL-10, IL-16, IL-17A, IL-22, IL-32, IL-36, hBD1), are produced by a combination of dendritic cells, monocytes, neutrophils and CD4+ T cells. IL-4 and IL-5 as key cytokines in the T_H2 axis are consistent with the findings of Mast cells in HS⁴¹, as well as the pruritus, which is frequently reported by patients. IL-10 in HS is produced by Treg cells² (although dendritic cells may also be a source), and whilst quantitatively the IL-10 signal appears paradoxically elevated, it can be explained by the up-regulation of T cells including Treg cells, which although significantly elevated from baseline, are not elevated enough in comparison to T_H17/IL-17/IL-22 signal to counteract this strong pro-inflammatory cascade². Further exploration of these cytokines may reveal the initial trigger(s) of the inflammatory cascade in HS, or correlations with known pro-inflammatory comorbidities.

Insights into pathogenesis of HS

In light of investigations in psoriasis and atopic dermatitis, the role of dendritic cells in HS needs to be clarified, as dendritic cell influx has been reported in histological studies^{41,42}, and they may contribute to the high IL-10 and IL-15 levels reported. IL-32 is a second cytokine produced by dendritic cells, but has only been reported in one study²⁹. Further research into the functional role of IL-32 in the activity of dendritic cells in HS would be of value. The role of IL-20, IL-22, IL-24 and IL-26 needs further clarification. IL-19, TSLP and CCL17 (TARC) have not yet been examined in HS and this is required in order to further explore the role of dendritic cell, monocyte and T cell activation and migration in this disease.

It is well established that smoking, obesity and diabetes are strongly associated with HS^{13–19,42,43}. The immunological effects of smoking include increase in number and responsiveness of dendritic cells, altered function of Treg cells and activation of Th17 pathways⁴⁴, whilst obesity and diabetes can result in production of IL-1 β , IL-6 and TNF- α through activated macrophages in adipose tissue^{45,46}. These potential mechanistic pathways (which may prime or contribute towards inflammation in HS) require validation in functional studies. However, if they are a significant contributor to inflammation, the presence or absence of these comorbidities need to be considered in future cytokine studies as confounding variables in order to identify significant biochemical markers independent of these other pro-inflammatory states that reflect the pathogenesis of HS.

The role of the microbiome^{42,43} in stimulating chronic inflammation has parallels in diabetes⁴⁷ and colonic inflammation⁴⁸

and the presence of *Porphyromonas* and *Peptoniphilus* species has been associated with a subpopulation of patients with HS⁴². *Porphyromonas* has been associated with systemic inflammation and atherosclerosis through aberrant toll-like-receptor 4 signalling⁴⁸ and is not part of the natural cutaneous flora⁴³. Altered cutaneous and gastrointestinal microbiome can also act via microbiome metabolites (including lipopolysaccharides, short chain fatty acids and bile salts)⁴⁹ through stimulation of myeloid dendritic cells via G Protein Coupled Receptors (including GPR41, GPR43 and GPR109A)^{49,50}. The microbiome may be implicated as a trigger factor for the initial inflammatory cascade in HS in a proportion of patients. Similarly, the presence of genetic polymorphisms as reported in HS⁵¹ have the potential to up-regulate inflammatory activity through shedding of IL-6R, IL-15R, TNF- α ⁵² as well as up-regulating the response of dendritic cells to LPS stimulation via ADAM17 (which has been demonstrated to be elevated in a published gene expression study of HS)⁵³. These pathways may be involved prior to the activation of keratinocyte-mediated inflammation, and hence, may reveal novel targets for new interventions to control the disease prior to the onset of destructive inflammation.

Limitations, interpretation and generalisability

The limitations to this study include the high degree of methodological variability (Table 5) and high impact of bias (Table 6) within the included studies. The lack of individual patient data has also prevented any further analysis into the contribution of comorbidities such as smoking and obesity to variable levels of cytokines in lesional tissue and/or serum. This, along with the high level of heterogeneity in many cytokines (Table 7), has resulted in analyses of the collated data being limited to descriptive analyses only and limited the generalisability of results.

Conclusions

Through this review we have catalogued the various cytokines that have been reported as elevated in lesional, peri-lesional tissue, serum or exudate of HS patients. We have also identified those cytokines with inconsistent results and identified methodological factors that may explain variability in findings. We have identified a number of missing links in disease pathogenesis with respect to cytokine actions and pathways that must be addressed in future work. Areas for further investigation include the role of dendritic cells in HS, the contribution of obesity, smoking, diabetes and the microbiome to cytokine profiles in HS, and examining the natural history of the disease through longitudinal measurements of cytokines over time.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

Extended data

OSF: Extend data. Data Collection Sheet Cytokine. Review HS. <https://doi.org/10.17605/OSF.IO/N2E7A22>

License: [CC0 1.0 Universal](#)

Reporting guidelines

OSF: PRISMA checklist for 'A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa'. <https://doi.org/10.17605/OSF.IO/N2E7A22>

License: [CC0 1.0 Universal](#)

Grant information

Supported in part by a grant from the National Center for Advancing Translational Sciences (NCATS) [UL1 TR001866], National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Hoffman LK, Ghias MH, Lowes MA: **Pathophysiology of hidradenitis suppurativa**. *Semin Cutan Med Surg*. 2017; **36**(2): 47–54. [PubMed Abstract](#) | [Publisher Full Text](#)
- Moran B, Sweeney CM, Hughes R, *et al.*: **Hidradenitis Suppurativa is characterized by Dysregulation of the Th17:Treg Cell Axis, which is Corrected by Anti-TNF Therapy**. *J Invest Dermatol*. 2017; **137**(11): 2389–2395. [PubMed Abstract](#) | [Publisher Full Text](#)
- Hessam S, Sand M, Gambichler T, *et al.*: **Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop**. *Br J Dermatol*. 2018; **178**(3): 761–767. [PubMed Abstract](#) | [Publisher Full Text](#)
- Hotz C, Boniotti M, Guuguin A, *et al.*: **Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa**. *J Invest Dermatol*. 2016; **136**(9): 1768–1780. [PubMed Abstract](#) | [Publisher Full Text](#)
- Kanni T, Tzanetakou V, Savva A, *et al.*: **Compartmentalized Cytokine Responses in Hidradenitis Suppurativa**. *PLoS One*. 2015; **10**(6): e0130522. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Banerjee A, McNish S, Shanmugam VK: **Interferon-gamma (IFN- γ) is Elevated in Wound Exudate from Hidradenitis Suppurativa**. *Immunol Invest*. 2017; **46**(2): 149–158. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Thomi R, Schlapbach C, Yawalkar N, *et al.*: **Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response**. *Exp Dermatol*. 2018; **27**(2): 172–177. [PubMed Abstract](#) | [Publisher Full Text](#)
- Jiménez-Gallo D, de la Varga-Martínez R, Ossorio-García L, *et al.*: **The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa**. *Mediators Inflamm*. 2017; **2017**: 2450401. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ten Oever J, van de Veerdonk FL, Joosten LA, *et al.*: **Cytokine Production Assays Reveal Discriminatory Immune Defects in Adults with Recurrent Infections and Noninfectious Inflammation**. *Clin Vacc Immunol*. 2014; **21**(8): 1061–1069. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Canoui-Poitrine F, Le Thuaut A, Revuz JE, *et al.*: **Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study**. *J Invest Dermatol*. 2013; **133**(6): 1506–11. [PubMed Abstract](#) | [Publisher Full Text](#)
- van der Zee HH, Jemec GB: **New Insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes**. *J Am Acad Dermatol*. 2015; **73**(5 Suppl 1): S23–26. [PubMed Abstract](#) | [Publisher Full Text](#)
- Zhou X, Fragala MS, McElhaney JE, *et al.*: **Conceptual and Methodological Issues relevant to Cytokine and inflammatory marker measurements in clinical research**. *Curr Opin Clin Nutr Metab Care*. 2010; **13**(5): 541–547. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ergun T: **Hidradenitis Suppurativa and the Metabolic Syndrome**. *Clin Dermatol*. 2018; **36**(1): 41–47. [PubMed Abstract](#) | [Publisher Full Text](#)
- Garg A, Birabakaran M, Strunk A: **Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States**. *J Am Acad Dermatol*. 2018; **79**(1): 71–76. [PubMed Abstract](#) | [Publisher Full Text](#)
- Lukach AJ, Saul MI, Ferris LK, *et al.*: **Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease**. *Dig Dis Sci*. 2018; **63**(3): 755–760. [PubMed Abstract](#) | [Publisher Full Text](#)
- Garg A, Papagermanos V, Mldura M, *et al.*: **Incidence of Hidradenitis Suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A**. *Br J Dermatol*. 2018; **178**(3): 709–714. [PubMed Abstract](#) | [Publisher Full Text](#)
- Sgambato JA, Jones BA, Caraway JW, *et al.*: **Inflammatory profile analysis reveals differences in cytokine expression between smokers, moist snuff users, and dual users compared to non-tobacco consumers**. *Cytoine*. 2018; **107**: 43–51. [PubMed Abstract](#) | [Publisher Full Text](#)
- Spoto B, Di Betta E, Mattace-Raso F, *et al.*: **Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesity**. *Nutr Metab Cardiovasc Dis*. 2014; **24**(10): 1137–43. [PubMed Abstract](#) | [Publisher Full Text](#)
- Rehman K Akash MS: **Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked?** *J Biomed Sci*. 2016; **23**(1): 87. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Frew J, Hawkes J Krueger J: **Cytokine Studies in Hidradenitis Suppurativa: A Systematic Review of Observational Studies**. PROSPERO 2018: CRD42018104664, Accessed 30 July 2018. [Reference Source](#)
- Moher D, Liberati A, Tetzlaff J, *et al.*: **Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement**. *PLoS Med*. 2009; **6**(7): e1000097. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Frew J: **A Systematic Review and Critical Evaluation of Inflammatory Cytokine Associations in Hidradenitis Suppurativa**. 2018. <http://www.doi.org/10.17605/OSF.IO/N2E7A>
- NIH NIoH: **Quality Assessment Tool for Observational Cohort and Cross Sectional Studies**. 2018; Accessed 30 July 2018. [Reference Source](#)
- Emelianov VU, Bechara FG, Gläser R, *et al.*: **Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa**. *Br J Dermatol*. 2012; **166**(5): 1023–1034. [PubMed Abstract](#) | [Publisher Full Text](#)
- Jiménez-Gallo D, de la Varga-Martínez R, Ossorio-García L, *et al.*: **Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa**. *Cytokine*. 2018; **103**: 20–24. [PubMed Abstract](#) | [Publisher Full Text](#)
- van der Zee HH, Laman JD, de Ruiter L, *et al.*: **Adalimumab (antitumour necrosis factor- α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an *in situ* and *ex vivo* study**. *Br J Dermatol*. 2012; **166**(2): 298–305. [PubMed Abstract](#) | [Publisher Full Text](#)
- Wolk K, Wenzel J, Tsaousi A, *et al.*: **Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa**. *Br J Dermatol*. 2017; **177**(5): 1385–1393. [PubMed Abstract](#) | [Publisher Full Text](#)
- Thomi R, Kakeda M, Yawalkar N, *et al.*: **Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa**. *J Eur Acad Dermatol Venereol*. 2017; **31**(12): 2091–2096. [PubMed Abstract](#) | [Publisher Full Text](#)
- Thomi R, Yerly D, Yawalkar N, *et al.*: **Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa**. *Br J Dermatol*. 2017; **177**(5): 1358–1366. [PubMed Abstract](#) | [Publisher Full Text](#)
- Lima AL, Karl I, Giner T, *et al.*: **Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa**. *Br J Dermatol*. 2016; **174**(3): 514–521. [PubMed Abstract](#) | [Publisher Full Text](#)
- Kelly G, Hughes R, McGarry T, *et al.*: **Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa**. *Br J Dermatol*. 2015; **173**(6): 1431–1439. [PubMed Abstract](#) | [Publisher Full Text](#)
- Schlapbach C, Hänn T, Yawalkar N, *et al.*: **Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa**. *J Am Acad Dermatol*. 2011; **65**(4): 790–8. [PubMed Abstract](#) | [Publisher Full Text](#)
- Kanni T, Argyropoulou M, Spyridopoulos T, *et al.*: **MABp1 Targeting IL-1 α for**

- Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.** *J Invest Dermatol.* 2018; **138**(4): 795–801.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Hawkes JE, Chan TC, Krueger JG: **Psoriasis pathogenesis and the development of novel targeted immune therapies.** *J Allergy Clin Immunol.* 2017; **140**(3): 645–653.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Bastarache JA, Koyama T, Wickersham NE, *et al.*: **Validation of a multiplex electrochemiluminescent immunoassay platform in human and mouse samples.** *J Immunol Methods.* 2014; **408**: 13–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Thompson DK, Huffman KM, Kraus WE, *et al.*: **Critical appraisal of four IL-6 immunoassays.** *PLoS One.* 2012; **7**(2): e30659.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. de Koning L, Liptak C, Shkreta A, *et al.*: **A multiplex immunoassay gives different results than singleplex immunoassays which may bias epidemiologic associations.** *Clin Biochem.* 2012; **45**(10–11): 848–851.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Tighe PJ, Ryder RR, Todd I, *et al.*: **ELISA in the multiplex Era: Potentials and Pitfalls.** *Proteomics Clin Appl.* 2015; **9**(3–4): 406–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. dupont NC, Wang K, Wadhwa PD, *et al.*: **Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants.** *J Reprod Immunol.* 2005; **66**(2): 175–191.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Brunner PM, Guttman-Yassky E, Leung DY: **The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.** *J Allergy Clin Immunol.* 2017; **139**(4S): S65–S76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. van der Zee HH, de Ruyter L, Boer J, *et al.*: **Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions.** *Br J Dermatol.* 2012; **166**(1): 98–106.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Ring HC, Thorsen J, Saunte DM, *et al.*: **The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls.** *JAMA Dermatol.* 2017; **153**(9): 897–905.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Guen-Revillet H, Jais JP, Ungeheuer MN, *et al.*: **The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A Prospective Metagenomic Study.** *Clin Infect Dis.* 2017; **65**(2): 282–291.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Qiu F, Liang CL, Liu H, *et al.*: **Impacts of cigarette smoking on immune responsiveness: Up and down or upside down?** *Oncotarget.* 2017; **8**(1): 268–284.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Kothari V, Galdo JA, Mathews ST: **Hypoglycemic agents and potential anti-inflammatory activity.** *J Inflamm Res.* 2016; **9**: 27–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Richards JL, Yap YA, McLeod KH, *et al.*: **Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases.** *Clin Transl Immunology.* 2016; **5**(5): e82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Basson A, Trotter A, Rodriguez-Palacios A, *et al.*: **Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease.** *Front Immunol.* 2016; **7**: 290.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Kramer CD, Genco CA: **Microbiota, Immune Subversion, and Chronic Inflammation.** *Front Immunol.* 2017; **8**: 255.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Kim CH: **Immune regulation by microbiome metabolites.** *Immunology.* 2018; **154**(2): 220–229.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Tan JK, McKenzie C, Marino E, *et al.*: **Metabolite-Sensing G Protein-Coupled Receptors-Facilitators of Diet-Related Immune Regulation.** *Annu Rev Immunol.* 2017; **35**: 371–402.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Frew JW, Vekic DA, Woods J, *et al.*: **A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa.** *Br J Dermatol.* 2017; **177**(4): 987–998.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Gooz M: **ADAM-17: the enzyme that does it all.** *Crit Rev Biochem Mol Biol.* 2010; **45**(2): 146–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Blok JL, Li K, Brodmerkel C, *et al.*: **Gene expression profiling of skin and blood in hidradenitis suppurativa.** *Br J Dermatol.* 2016; **174**(6): 1392–4.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Referee Status:



Version 1

Referee Report 04 March 2019

<https://doi.org/10.5256/f1000research.18879.r43994>



Evangelos Giamarellos-Bourboulis  ^{1,2}

¹ Attikon University Hospital, Athens, Greece

² National and Kapodistrian University of Athens, Athens, Greece

This is a long time needed review trying to shed light in the pathogenesis of hidradenitis suppurativa (HS). My concerns are coming from the biggest hurdle the authors had to overcome from the very beginning of their attempt i.e. the great heterogeneity of the existing evidence. Due to this, I find over-exaggerated the conducted approach to set-up a mechanistic interpretation for the disease. I believe that the heterogeneity is so vast that it is almost impossible to suggest the pathways implicated in the pathogenesis of HS. To this end, I suggest that the mechanistic parts are omitted and Figure 2 as well.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Yes

Are the conclusions drawn adequately supported by the results presented in the review?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Immunology, genetics, hidradenitis, anti-cytokine therapies

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Referee Report 25 February 2019

<https://doi.org/10.5256/f1000research.18879.r43995>



Aude Nassif 

Institut Pasteur, Medical Center, Paris, France

This very instructive study aims at analyzing previous cytokine studies in HS patients, in skin tissue, blood, serum and exudates, to assess relevancy and reliability of these studies.

The authors have performed an extensive work, methods seem perfectly appropriate. The authors are very critical and rigorous in their approach, looking for confounding factors, which is highly desired.

The authors could also mention that genetic heterogeneity may play a role in the diversity of results and encourage using similar phenotypes for future studies.

This analysis brings up a very important and honest contribution to the current knowledge in cytokines involved in HS and therefore deserves indexing.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: microbiology, genetics, therapeutics, clinical forms of HS and associated diseases

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 07 February 2019

<https://doi.org/10.5256/f1000research.18879.r43493>



Barbara Horváth , **Lisette Prens**

Department of Dermatology, University of Groningen, Groningen, The Netherlands

Thank you for the opportunity to review this manuscript and congratulations to the authors for their great efforts in putting this systematic review together. Research on the role of cytokines in HS is important, as it may lead to new targets for therapy and a better understanding of the pathophysiology of HS.

Summary

This systematic review focused on collecting all data published on cytokine studies in tissue, blood, serum and exudate in hidradenitis suppurativa. 81 discrete cytokines were examined in HS patients

(n=564) and control patients (n=198) in 19 studies. Methodology varied greatly among studies, which were generally of low quality. When measuring levels of cytokines, substantial variance was found and the majority of cytokines showed heterogeneity. IL-17 signalling appeared to be a significant component. Suggestions for further research were discussed.

Questions

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes.

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes. However, I wonder why the term 'hidradenitis suppurativa' is not in the search strategy and 'hidradenitidis suppurative' is? 'Hidradenitidis' is not an existing word, as far as I know and will not provide any search results. Please adjust.

Is the statistical analysis and its interpretation appropriate?

Yes, as far as I can judge as a non-statistician. The analyses used are ones I have little experience with myself. I'll refrain from commenting on this section.

Are the conclusions drawn adequately supported by the results presented in the review?

Partly. The last conclusion 'examining the natural history of the disease through longitudinal measurements of cytokines over time' is not discussed anywhere else in this article. First, I suggest changing 'history' to 'course'. Moreover, I am wondering, how the authors propose to do this. Monitoring the natural course of the disease, would mean patients cannot receive any treatment for their HS, during this proposed study. Depending on how long the natural course is meant to be monitored, I don't think it is ethical to withhold patients from treatment.

Please elaborate on this conclusion with a specific proposal or otherwise rephrase or maybe leave out this conclusion.

Other comments

Page 9 last paragraph/Page 28 – 1st paragraph: You state that 'psoriasiform epidermal hyperplasia is seen in HS'. Please provide a reference for this statement. The reference provided only references to the pathway likely responsible for this in psoriasis.

Page 28 – 4th paragraph: 'These potential mechanistic pathways (which may prime or contribute towards inflammation in HS) require validation in functional studies.' Could you please provide an example on how such a functional study should be designed to produce reliable results?

Table 4: the abbreviation 'Lpa' is not clarified in the key section of the table. Does 'Le' (page 11, IL-1a, first row) mean lesion exudate?

Table 6: the number four of question four is missing in the top row of the table on both pages (24-25). Please insert.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Yes

Are the conclusions drawn adequately supported by the results presented in the review?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Hidradenitis suppurativa

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research